The UCSF spinout turned an academic pathogen-hunting assay into a 48-hour clinical service. Its next challenge is bigger than sequencing: persuading hospitals to order one broad test earlier, without pretending every strange read is the answer.
Biotia is a New York-based health-tech company that fights infectious diseases by combining next-generation DNA sequencing with AI-driven software. Its metagenomic platform identifies bacteria, fungi, parasites and viruses - plus antimicrobial-resistance markers - from a single sample against a curated database of more than 16,000 microbial species. Spun out of the Jacobs Technion-Cornell Institute at Cornell Tech and operating a CLIA-certified lab in New York City, Biotia turns a single microbiome test into an actionable clinical report to help providers diagnose hard-to-detect infections and support pathogen surveillance from the hospital to outer space.